Literature DB >> 8945892

Ischemic preconditioning in human and rat ventricle.

J C Cleveland1, M M Wollmering, D R Meldrum, R T Rowland, T F Rehring, B C Sheridan, A H Harken, A Banerjee.   

Abstract

The signal transduction of ischemic preconditioning involves activation of endogenous receptor-based systems, including alpha 1-adrenoceptors and adenosine receptors. Whereas preconditioning protects against ischemia-reperfusion injury, it is unknown whether this protective strategy might be useful clinically. Furthermore, human atrium has been successfully preconditioned, but it is unknown whether human ventricle can be functionally protected against hypoxia-reoxygenation. To study these questions, isolated rat ventricle and human ventricular trabeculae were suspended in an organ bath and subjected to 30 min of hypoxia and 60 min of reoxygenation. In the rat ventricle, preconditioning was induced by 5 min of rapid pacing at 3 Hz in hypoxic buffer without glucose (simulated ischemia), alpha 1-adrenoceptor stimulation (phenylephrine), or adenosine receptor stimulation (adenosine). In the human trabeculae the effects of preceding simulated ischemia and alpha 1-adrenoceptor and adenosine receptor stimulation were examined against hypoxia-reoxygenation. In the rat, pretreatment with simulated ischemia and alpha 1-adrenoceptor and adenosine receptor stimulation improved recovery of developed tension (56 +/- 3, 56 +/- 4, and 58 +/- 2%, respectively) compared with control trabeculae (25 +/- 2%) after hypoxia-reoxygenation (P < 0.05). In human trabeculae, simulated ischemic preconditioning and alpha 1-adrenoceptor and adenosine receptor stimulation augmented recovery of developed tension (65 +/- 5, 59 +/- 6, and 60 +/- 3%, respectively) compared with control (29 +/- 2%) after hypoxia-reoxygenation (P < 0.05). We conclude that functional cardioadaptation (preconditioning) against hypoxia-reoxygenation injury in rat and human myocardium exists and that alpha 1-adrenergic and adenosine receptor signaling participate in conferring this protection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8945892     DOI: 10.1152/ajpheart.1996.271.5.H1786

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

Review 1.  Organ preconditioning: the past, current status, and related lung studies.

Authors:  Shi-ping Luh; Pan-chyr Yang
Journal:  J Zhejiang Univ Sci B       Date:  2006-05       Impact factor: 3.066

2.  Effects of hypoxic preconditioning on the hypoxic-reoxygenated atria from fed and fasted rats.

Authors:  G Testoni; S Cerruti; P Kade; M Carregal; A Varela; E A Savino
Journal:  J Physiol Biochem       Date:  2000-12       Impact factor: 4.158

Review 3.  Adenosine receptors and reperfusion injury of the heart.

Authors:  John P Headrick; Robert D Lasley
Journal:  Handb Exp Pharmacol       Date:  2009

4.  Effects of fasting and hypoxic preconditioning on the hypoxic-reoxygenated ventricular strips of the rat heart.

Authors:  S Cerruti; G Testoni; V Dalamon; P Kade; A Varela; E A Savino
Journal:  J Physiol Biochem       Date:  2002-06       Impact factor: 4.158

Review 5.  Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure.

Authors:  Brian C Jensen; Timothy D O'Connell; Paul C Simpson
Journal:  J Mol Cell Cardiol       Date:  2010-11-28       Impact factor: 5.000

Review 6.  Adaptive and maladaptive mechanisms of cellular priming.

Authors:  D R Meldrum; J C Cleveland; E E Moore; D A Partrick; A Banerjee; A H Harken
Journal:  Ann Surg       Date:  1997-11       Impact factor: 12.969

Review 7.  Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance.

Authors:  Timothy D O'Connell; Brian C Jensen; Anthony J Baker; Paul C Simpson
Journal:  Pharmacol Rev       Date:  2013-12-24       Impact factor: 25.468

8.  {alpha}1-Adrenergic receptor subtypes in nonfailing and failing human myocardium.

Authors:  Brian C Jensen; Philip M Swigart; Teresa De Marco; Charles Hoopes; Paul C Simpson
Journal:  Circ Heart Fail       Date:  2009-08-06       Impact factor: 8.790

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.